ClinicalTrials.gg
TerminatedNCT03580694Updated Mar 13, 2020

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Phase 1 interventional study of REGN4659 and Cemiplimab in Carcinoma, Non-Small-Cell Lung, sponsored by Regeneron Pharmaceuticals. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-13.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

Why this study was terminated
Program reprioritization

From the registry’s dates

  • Primary completion was Dec 2019, 6 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
27th of 29
17 · median 61
Started
2018
with 3 others
Phase 1
Only one
of the 29
Registered
5th of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 27th largest by enrollment, is one of 4 that started in 2018, is the only one in phase 1, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • Non-Small Cell Lung Cancer
  • NSCLC
  • Anti-PD-1
  • Anti-CTLA-4
  • Immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

KEY Inclusion Criteria:

  1. Patients with or cytologically documented squamous or non-squamous NSCLC with unresectable stage IIIB or stage IV disease
  2. Combination dose escalation cohorts: Treatment-experienced patients who have received no more than 3 including no more than 2 lines of cytotoxic chemotherapy, and for whom no available therapy has a high probability to convey clinical benefit.
  3. Dose escalation cohort C: Anti-/PD-L1 naïve patients who have received 1 to 2 prior lines of cytotoxic chemotherapy including a platinum doublet-containing regimen
  4. Expansion cohort(s): Anti-PD-1/PD-L1 experienced patients who have progressed while receiving therapy or within 6 months of stopping therapy for stage III or IV disease. Patients must not have permanently discontinued anti-PD-1/PD-L1 therapy due to treatment related AE. Patients must have received one line of anti-PD--1/PD-L1 immunotherapy. Patients may also have received one line of chemotherapy

KEY Exclusion Criteria:

  1. Expansion cohort(s) only: Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime
  2. Active or untreated or spinal cord compression. Patients are eligible if central nervous system (CNS) are adequately treated and patients have neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to enrollment. Patients must be off ( doses of) therapy
  3. Expansion cohort(s) only: Patients with tumors tested positive for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene mutations or ROS1 fusions.
  4. Radiation therapy within 2 weeks prior to enrollment and not recovered to baseline from any AE due to radiation
  5. Patients who received prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody
  6. Previous treatment with idelalisib (ZYDELIG®) at any time

Note: Other protocol defined inclusion/ exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Cemiplimab Monotherapy

    In a single dose escalation cohort, participants will receive cemiplimab alone.

    Drug: Cemiplimab

  • Experimental
    Combination Therapy

    Dose Escalation cohorts: In 3 dose escalation cohorts, participants will receive a lead-in dose of REGN4659 followed by REGN4659 and cemiplimab in combination. In 4 dose escalation cohorts, participants will receive REGN4659 with cemiplimab in combination. Dose Expansion cohorts: In dose expansion cohorts, participants will receive combination regimens of REGN4659 and cemiplimab.

    Drug: REGN4659 · Drug: Cemiplimab

Interventions

  • DrugREGN4659

    REGN4659 will be administered by intravenous (IV) infusion.

  • Cemiplimab will be administered by intravenous (IV) infusion.

    Also known as: REGN2810

06

What researchers measure

Primary outcomes

  1. Rate of dose limiting toxicities (DLTs) during the dose escalation phase

    Time frame: Up to week 126

  2. Rate of treatment emergent adverse events (TEAEs)

    Time frame: Up to week 126

  3. Rate of immune-related adverse events (irAEs)

    Time frame: Up to week 126

  4. Rate of serious adverse events (SAEs)

    Time frame: Up to week 126

  5. Rate of deaths

    Time frame: Up to week 126

  6. Laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE])

    Time frame: Up to week 126

  7. Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 during the dose expansion phase

    Time frame: Up to week 126

  8. REGN4659 and cemiplimab concentrations in serum over time

    Time frame: Up to week 126

Secondary outcomes

  1. ORR based on RECIST 1.1 during the dose escalation phase

    Time frame: Up to week 126

  2. ORR based on immune-based therapy Response Evaluation Criteria (iRECIST)

    Time frame: Up to week 126

  3. Best overall response (BOR)

    Time frame: Up to week 126

  4. Duration of response (DOR)

    Time frame: Up to week 126

  5. Disease control rate

    Time frame: Up to week 126

  6. Progression-free-survival (PFS) based on RECIST 1.1

    Time frame: Up to week 126

  7. PFS based on iRECIST

    Time frame: Up to week 126

  8. Overall survival (OS)

    Time frame: Up to week 126

07

Study locations

6 sites
  • Regeneron Investigational Site
    Chicago, Illinois 60637, United States
  • Regeneron Investigational Site
    Grand Rapids, Michigan 49546, United States
  • Regeneron Investigational Site
    Charlotte, North Carolina 28204, United States
  • Regeneron Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Regeneron Investigational Site
    Nashville, Tennessee 37203, United States
  • Regeneron Investigational Site
    San Antonio, Texas 78229, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Dec 2019, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2018
First posted
Jul 9, 2018
StartActual
Jun 27, 2018
Primary completionActual
Dec 4, 2019
CompletionActual
Dec 4, 2019
Last update
Mar 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03580694
Responsible party
Sponsor
First posted
Jul 9, 2018
Start date
Jun 27, 2018
Primary completion
Dec 4, 2019
Completion
Dec 4, 2019
Last update
Mar 13, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion